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In 1995, the genomic sequence of the bacteria Haemophilus
influenzae was the first complete genomic sequence of a
free-living organism to be published [1]. Since then, scientists
have totally sequenced the genomes of more than one
hundred bacteria and completed genetic maps of large multi-
cellular organisms [2–5]. The draft sequence of the human
genome, recently published by the Human Genome Project
public consortium [6] and by a private company [7], repre-
sents a milestone in science. Today, the genetic blueprint for
a human is nearly completed and covers 96% of the genome.
Embedded within our genomes are the sequences of the
approximately 30,000 genes that underlie human biology and
medicine. As we enter the post genome-sequencing era, we
are already facing new challenges. Successful translation of
this structural knowledge into clinical benefits will depend
upon our ability to relate individual genes to specific dis-
eases, to find the genetic variations that influence an individu-
al’s risk of becoming ill, and to use genetic information to
tailor drug therapy. The purpose of this review is to put some
of the predictable consequences of the advances in
genomics into clinical perspective.
Single-nucleotide polymorphisms: learning
from our differences
Most common diseases and many drug responses have been
shown to be influenced by inherited differences in our genes.
Thus, studying generic variance can improve our understand-
ing and treatment of disease. If a region of the human
genome is sequenced from two randomly chosen individuals,
99.3% of the examined DNA will be identical [8]. Much of the
genetic variation between individuals lies in differences
known as single-nucleotide polymorphisms (SNPs); a single
base is swapped for an alternate, and both versions exist in
the general population at frequencies greater than 1% [8]. As
SNPs constitute the bulk of human genetic variation, they can
be used to track inheritance of genes in traditional family-
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Abstract
Since most common diseases have been shown to be influenced by inherited variations in our genes,
completion of the Human Genome Project and mapping of the human genome single-nucleotide
polymorphisms will have a tremendous impact on our approach to medicine. New developments in
genotyping techniques and bioinformatics, enabling detection of single-nucleotide polymorphisms,
already provide physicians and scientists with tools that change our understanding of human biology. In
the near future, studies will relate genetic polymorphisms to features of critical illnesses, increased
susceptibility to common diseases, and altered response to therapy. Novel insights into the contribution
of genetic factors to critical illnesses and advances in pharmacogenomics will be used to select the
most effective therapeutic agent and the optimal dosage required to elicit the expected drug response
for a given individual. Implementation of genetic criteria for patient selection and individual assessment
of the risks and benefits of treatment emerges as a major challenge to the pharmaceutical industry.
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based linkage studies. By epidemiological association, SNPs
can also be used to test susceptibilities to common diseases
such as heart disease, cancer, and diabetes.
Based on the promise of SNP research, an international
subset of academic centers, pharmaceutical companies, and a
private foundation teamed up to create the SNP Consortium in
1999. Whereas the initial goal of the consortium was to dis-
cover 300,000 SNPs that would be freely available by April
2001, this has been exceeded, and the SNP, in collaboration
with the International Human Genome Sequencing Consor-
tium, has created a catalogue of more than 1.4 million SNPs
[9]. This publicly available SNP map promises to advance our
knowledge of the links between genes and diseases.
Linking SNPs to phenotypes: disease
markers or more?
One of the most difficult challenges faced by physicians and
scientists is to establish the link between gene variations and
a disease. Of the 1.4 million SNPs currently on the public
map, only 60,000 are located in protein coding regions,
called exons, and relatively few of these transform amino
acids [9]. The SNPs that change the amino acid sequence,
and variants in gene regulatory regions that control protein
expression levels, are most likely to have a direct impact on
the protein product of a gene [10]. In cases where change of
a single base in the genome sequence is sufficient to cause
disease, it has become possible to identify this change and
improve our understanding of the disease. For instance,
sickle cell anemia is caused by the substitution of a thymine
for adenine at a single position in the gene that encodes the
hemoglobin molecule.
Using ever more powerful approaches, literally hundreds of
rare human diseases have been related to genetic defects.
However, the genetic contributions have proven more difficult
to establish for the common diseases that account for most
morbidity and mortality. In most cases, the influence of gene
variants is subtle and the risk of contracting the disease is
also influenced by environmental factors [10]. Even if the
causal mutations are common in the population, their effects
will, therefore, be difficult to discover. As the effects of any
given SNP may be modest, it will be necessary to study large
numbers of patient samples to observe associations in a
reproducible fashion. Therefore, comprehensive studies will
rely on the development of fast and efficient tools to identify
the small number of relevant SNPs out of the millions in the
human genome.
A phenomenon called linkage disequilibrium should permit
the use of SNPs to track associations to disease, without
necessarily finding each functionally relevant SNP before-
hand. In a certain region, SNPs often track together in the
population. In linkage disequilibrium, such nearby SNPs can
serve as proxies for each other in a disease study. Hence, a
subset of SNPs spaced throughout the genome might allow a
comprehensive test of common genetic variation across the
entire genome. Although the specific number of SNPs
needed for linkage disequilibrium studies is unknown, the 1.4
million SNPs in the public domain should offer a sufficient
number to explore most regions of the genome.
Impact of SNP research on clinical trial
design
Besides all the consequences of genetics on our understand-
ing of the pathophysiology of critical illnesses, advances in
SNP research also promise to change current practices in
clinical trials [11]. The SNP effort will undoubtedly serve as
the bedrock of pharmacogenomics, the emerging field of per-
sonalized medicine in which drugs and preventative strate-
gies are specifically tailored to suit an individual’s genetic
profile. One can speculate that many of the recent advances
in genetics will soon be brought into clinical trials with two
main directions. First, whereas treatment allocation has been
based mainly on phenotype, genetic characterization based
on the genetic profile of an individual will help researchers to
identify suitable subjects to test a working hypothesis. This
approach will also facilitate interpretation of the results of
clinical trials, and ultimately enable clinicians to tailor treat-
ment to patients with specific genotype. For instance, an
analysis based on the main studies of anti-tumor necrosis
factor (TNF) strategies in septic patients found an absolute
decrease in mortality of 3.5%, suggesting that these thera-
pies could be beneficial in septic patients with uncontrolled
TNF release [12]. Targeting patients whom carry the TNF2
allele and produce high levels of TNF-α [13], may reveal a
beneficial effect of treatment with anti-TNF antibodies for
septic shock [14,15]. Second, as interindividual variability in
the response to drugs remains a substantial clinical problem,
a major objective of pharmacogenomic research is to
decrease adverse responses to therapy through determina-
tion of adequate therapeutic targets and genetic polymor-
phisms that alter drug specificity, metabolism, and toxicity
[11]. Ultimately, genetic information will be used to select the
most effective therapeutic agent and the optimal regimen to
elicit the expected drug response for a given individual.
Hence, the implementation of genetic criteria to select patient
populations and of individual assessment of the risks and
benefits of treatment is emerging as a major challenge for
pharmaceutical companies.
Among the hurdles to overcome for successful integration of
genetics in clinical practices, it will be necessary to improve
our ability to detect SNPs at a lower cost. Methods to identify
SNPs are based on modifications of the traditional DNA
sequencing approach, which can use a range of detection
methods, such as radioactivity, fluorescence resonance
energy transfer, or fluorescence polarization. More recently,
arrays on glass slides, DNA chip-based microarrays, and
mass spectrometry genotyping technologies have been intro-
duced to simultaneously determine the genotype of large
numbers of SNPs [16–18]. It is not yet clear which of theseCritical Care    June 2002 Vol 6 No 3 Chiche et al.
powerful methods will become most useful. At a current
average price of one dollar per genotype, SNP detection in
large-scale genotyping studies is still prohibitively expensive.
Even at one cent per genotype, the cost per patient in a
typical association study testing 100,000 SNPs will possibly
add one million US dollars to the cost of a clinical trial [19].
Significant advances will be necessary to make extensive
genotyping a standard part of clinical trials.
Perspectives and limitations of SNP research
There are still many significant technical and analytical prob-
lems that must be solved before the promise of SNPs can be
fulfilled. Whereas the current SNP maps provide us with
invaluable tools to track statistically significant associations
between SNPs and disease or drug response, we do not fully
understand the genetic architecture of common traits under-
lying disease susceptibility and variability in drug response.
Interpretation of association studies is complicated by the
number of genes, the number of variants in each gene, and
the frequency of a variant within a population. Location of a
variant SNP in the coding region, the regulatory region, or the
noncoding region of the genome also affects susceptibility to
disease in a way that is still unclear. In addition, the interac-
tion of individual SNPs and the degree to which they track
together in linkage disequilibrium may be of the utmost impor-
tance in the determination of a given phenotype.
Other issues must be addressed to unlock the full potential of
SNPs. Given the large number of SNPs and the low probabil-
ity that any specific one causes disease, the sample sizes in
association studies need to be large enough to achieve ade-
quate statistical power. This also raises the problem of accu-
rately phenotyping individuals, since the same disease may
manifest itself with different patterns in different patients.
Finally, new ethical issues will arise, which will have to be
solved as SNP technology improves and becomes widely
used. Whereas current genetic tests typically track single-
disease genes, SNPs will provide tests that associate a
genetic profile with individual predisposition to a broad list of
diseases. Physicians and scientists are just beginning to
address the question of how to keep such sensitive pheno-
typical and genotypical information confidential so that it is
not misused by either employers or insurance companies.
Most importantly, our patients will have to cope with this infor-
mation, sometimes left in the expectation of preventive strate-
gies and therapeutic solutions.
As the first round of human genome sequencing nears com-
pletion, identifying functions for each of the 30,000 or more
human genes, and determining which of these genes play a
role in disease, will emerge as one of the great challenges of
twenty-first century biomedicine. Yet, physicians and scien-
tists have undertaken the task of characterizing and cata-
loging a shared universe of generic differences that underlies
our susceptibility to diseases and alters our response to
drugs. Although this work appears to be quite demanding, it
provides tremendous opportunities in our search to under-
stand, and ultimately treat, diseases that account for most of
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